These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 9851642)

  • 1. ALS/MND and the perspective of health economics.
    Gray AM
    J Neurol Sci; 1998 Oct; 160 Suppl 1():S2-5. PubMed ID: 9851642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost utility analysis of riluzole for the treatment of amyotrophic lateral sclerosis in the UK.
    Tavakoli M; Malek M
    J Neurol Sci; 2001 Oct; 191(1-2):95-102. PubMed ID: 11676998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of treatments for amyotrophic lateral sclerosis: a review of the literature.
    Ginsberg G; Lowe S
    Pharmacoeconomics; 2002; 20(6):367-87. PubMed ID: 12052096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Cost-Effectiveness Framework for Amyotrophic Lateral Sclerosis, Applied to Riluzole.
    Thakore NJ; Pioro EP; Udeh BL; Lapin BR; Katzan IL
    Value Health; 2020 Dec; 23(12):1543-1551. PubMed ID: 33248509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of riluzole in amyotrophic lateral sclerosis. Italian Cooperative Group for the Study of Meta-Analysis and the Osservatorio SIFO sui Farmaci.
    Messori A; Trippoli S; Becagli P; Zaccara G
    Pharmacoeconomics; 1999 Aug; 16(2):153-63. PubMed ID: 10539396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shoulder acute pain in primary health care: is retraining GPs effective? The SAPPHIRE randomized trial: a cost-effectiveness analysis.
    McKenna C; Bojke L; Manca A; Adebajo A; Dickson J; Helliwell P; Morton V; Russell I; Torgerson D; Watson J
    Rheumatology (Oxford); 2009 May; 48(5):558-63. PubMed ID: 19258378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Cochrane Database Syst Rev; 2002; (2):CD001447. PubMed ID: 12076411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data.
    Briggs AH; Lozano-Ortega G; Spencer S; Bale G; Spencer MD; Burge PS
    Value Health; 2006; 9(4):227-35. PubMed ID: 16903992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of neonatal extracorporeal membrane oxygenation based on 7-year results from the United Kingdom Collaborative ECMO Trial.
    Petrou S; Bischof M; Bennett C; Elbourne D; Field D; McNally H
    Pediatrics; 2006 May; 117(5):1640-9. PubMed ID: 16651318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-benefit analysis of riluzole for the treatment of amyotrophic lateral sclerosis.
    Ginsberg GM; Lev B
    Pharmacoeconomics; 1997 Nov; 12(5):578-84. PubMed ID: 10174324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness associated with amyotrophic lateral sclerosis: some questions and answers pending.
    Fiorentino G; Esquinas AM
    Amyotroph Lateral Scler Frontotemporal Degener; 2018 May; 19(3-4):315-316. PubMed ID: 29191046
    [No Abstract]   [Full Text] [Related]  

  • 13. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Moore DH
    Cochrane Database Syst Rev; 2000; (2):CD001447. PubMed ID: 10796796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness: summary.
    Ringel SP
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2002; 3 Suppl 1():S67-9. PubMed ID: 12396813
    [No Abstract]   [Full Text] [Related]  

  • 15. Hepatic resection for colorectal liver metastases: A cost-effectiveness analysis.
    Beard SM; Holmes M; Price C; Majeed AW
    Ann Surg; 2000 Dec; 232(6):763-76. PubMed ID: 11088071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Service provision for patients with ALS/MND: a cost-effective multidisciplinary approach.
    Corr B; Frost E; Traynor BJ; Hardiman O
    J Neurol Sci; 1998 Oct; 160 Suppl 1():S141-5. PubMed ID: 9851665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of clinical factors, riluzole and therapeutic interventions on ALS survival: a population based study in Modena, Italy.
    Georgoulopoulou E; Fini N; Vinceti M; Monelli M; Vacondio P; Bianconi G; Sola P; Nichelli P; Mandrioli J
    Amyotroph Lateral Scler Frontotemporal Degener; 2013 Sep; 14(5-6):338-45. PubMed ID: 23373475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of systemic and regional chemotherapy for the treatment of patients with unresectable colorectal liver metastases.
    Durand-Zaleski I; Earlam S; Fordy C; Davies M; Allen-Mersh TG
    Cancer; 1998 Sep; 83(5):882-8. PubMed ID: 9731890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of an economic model to assess the cost effectiveness of asthma management strategies.
    Price MJ; Briggs AH
    Pharmacoeconomics; 2002; 20(3):183-94. PubMed ID: 11929348
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.